600
Views
0
CrossRef citations to date
0
Altmetric
Interview

Neuropathic Pain: Research, Treatment and Education

Pages 509-511 | Published online: 02 Nov 2011
 

Abstract

Nanna Finnerup graduated from the Medical School at Aarhus University, Denmark, in 1993, and after an internship worked at the Department of Neurology and Clinical Neurophysiology at the University of Copenhagen, Denmark. Since 1998 she has worked at the Danish Pain Research Center at Aarhus University. She obtained her degree of Doctor of Medical Sciences from Aarhus University in 2008, and is currently Associate Research Professor at the Danish Pain Research Center. Her main research interest is the pathophysiology and therapy of neuropathic pain, with particular focus on the mechanisms of central pain and pharmacological treatment of neuropathic pain. Dr Finnerup is a Management Committee Member of the Special Interest Group on Neuropathic Pain (NeuPSIG) of the International Association for the Study of Pain and a board member of the Scandinavian Association for the Study of Pain (SASP). She is a member of the Editorial Advisory Board of the Scandinavian Journal of Pain, the Encyclopedia of Pain and Pain Management.

Financial & competing interests disclosure

N Finnerup receives research funding from the Europain Investigational Medicines Initiative, which is a public–private partnership between the pharmaceutical industry and the EU. N Finnerup has also received research funding from Grünenthal and served as consultant for Grünenthal and Pfizer. N Finnerup has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

N Finnerup receives research funding from the Europain Investigational Medicines Initiative, which is a public–private partnership between the pharmaceutical industry and the EU. N Finnerup has also received research funding from Grünenthal and served as consultant for Grünenthal and Pfizer. N Finnerup has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.